Ted, V1,
My take on this (not that it is worth much) is that we are seeing a lot of fuss made over a matter of extremely small significance. No one, I trust, was buying Guilford at 25 - 30 for its Gliadel profit potential. Ted, you made a good point: At best, and all in due time, Gliadel (and related chemotheraputic polymer delivery systems) profits could be expected to absorb some portion of the (neurology driven) burn rate. At this stage of the game, a couple of Gliadel dollars, more or less, would not change a thing.
Like you, I am also *much* more interested in the markets for stroke, Alzheimer's, Parkinson's, head trauma, ALS, etc., etc. This is where the potential lies. And Guilford has on its side a hoard of cash, a strong and hungry partner, and lots of worthwhile science. What else does a development-stage biotech company need?
RB
|
